Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Infographic showing Laplace Interventional’s TRIUMPH pivotal trial, highlighting treatment of the first three patients, the FDA-authorised randomised study design, and plans to enrol about 400 patients for its investigational tricuspid valve.
Medical Devices & Diagnostics

Laplace Interventional is taking on an approved tricuspid valve with TRIUMPH, but can its new implant deliver better outcomes?

Laplace Interventional has treated the first three patients in its FDA-authorised TRIUMPH pivotal trial, moving its investigational tricuspid valve into a randomised comparison with commercial replacement technology. With approximately 400 patients planned for the main study, the company must demonstrate meaningful safety and effectiveness in an increasingly competitive structural heart market.

Read More
Infographic highlighting Eisai’s upcoming presentation of five-year lecanemab and real-world Alzheimer’s disease data at CTAD 2026, featuring brain and neuron illustrations alongside key efficacy and safety questions.
Pharma & Biotech

Eisai is about to reveal five years of lecanemab treatment data, but will long-term therapy justify its benefits and risks?

Eisai will present five-year lecanemab and real-world Alzheimer's data at CTAD 2026. Explore the key efficacy and safety questions.

Read More
Infographic showing Glenmark's new 160,000-square-foot pharmaceutical distribution hub in Allentown, highlighting its supply network serving 321 locations across 43 U.S. states.
Pharma & Biotech

Glenmark Pharmaceuticals opens 160,000 sq ft US distribution hub serving 321 locations across 43 states

Glenmark opens its 160,000 sq ft Allentown distribution hub, serving 321 locations across 43 US states. Explore its supply-chain strategy.

Read More
Infographic showing Eli Lilly’s increased 2026 revenue guidance of $91 billion to $92 billion, highlighting surging Mounjaro and Zepbound sales, pipeline growth opportunities and key execution and competition risks.
Pharma & Biotech

Eli Lilly just lifted its 2026 sales outlook by $5.5bn, but can surging GLP-1 demand keep outrunning price pressure?

Eli Lilly raises 2026 revenue guidance to $91bn–$92bn as Mounjaro and Zepbound sales surge. Explore its earnings, pipeline and risks.

Read More
Infographic highlighting Setara’s $90 million financing to advance STAR-0871 for Charcot-Marie-Tooth disease type 2C (CMT2C) and overactive bladder, featuring neurological and bladder illustrations and the continuation of Actio’s development pipeline following the Jazz acquisition.
Pharma & Biotech

Setara Biosciences raises $90m to advance STAR-0871 for CMT2C and overactive bladder after Jazz acquisition

Setara raises $90m to advance STAR-0871 for CMT2C and overactive bladder, carrying forward Actio’s pipeline after the Jazz acquisition.

Read More
Infographic highlighting Alkermes’ 180-patient Phase 2 ALKS 7290 depression trial, featuring a neural brain illustration and key details about orexin activation alongside antidepressants and safety evaluation.
Pharma & Biotech

Alkermes launches 180-patient Phase 2 ALKS 7290 trial testing orexin activation in major depression

Alkermes starts a 180-patient Phase 2 ALKS 7290 depression trial, testing orexin activation alongside antidepressants and assessing safety.

Read More
Infographic showing Latus Bio’s preclinical AAV delivery data, highlighting capsids reaching 80% of kidney glomeruli and up to 60% of cortical neurons, while noting that human safety and efficacy remain unproven.
Pharma & Biotech

Latus Bio’s new AAV capsids reach 80% of kidney glomeruli, but can better delivery translate into safer gene therapies?

Latus Bio reports AAV capsids reaching 80% of kidney glomeruli and up to 60% of cortical neurons, with human safety and efficacy unproven.

Read More
Infographic showing Pretzel Therapeutics receiving UK clinical trial authorisation for PX578, featuring mitochondrial research imagery and highlighting planned Phase 2 testing in POLG disease before the end of 2026.
Pharma & Biotech

Pretzel Therapeutics receives UK trial authorisation for PX578 ahead of Phase 2 POLG disease study

Pretzel Therapeutics gains UK trial authorisation for PX578, paving the way for Phase 2 testing in POLG disease before year-end 2026.

Read More
Infographic showing Immunome’s varegacestat entering European Medicines Agency review, highlighting strong RINGSIDE trial results and key remaining uncertainties around safety, competition and final approval.
Pharma & Biotech

Immunome’s varegacestat cut progression risk by 84%, but can it challenge an already approved European desmoid tumour treatment?

Immunome's varegacestat enters EMA review after strong RINGSIDE results, but safety, competition and approval remain key uncertainties.

Read More
Eurosets introduces Trilly Baby oxygenator for infant cardiac surgery
Medical Devices & Diagnostics

Eurosets unveils Trilly Baby oxygenator for infant heart surgery ahead of planned European rollout

Eurosets unveils Trilly Baby for infant heart surgery, targeting CE marking before a planned 14-centre European rollout in January 2027.

Read More